These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21242246)

  • 1. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
    Smolen JS; Boers M; Abadie EC; Breedveld FC; Emery P; Bardin T; Goel N; Ethgen DJ; Avouac BP; Durez P; Flamion B; Laslop A; Miossec P; Reiter S; Reginster JY;
    Rheumatology (Oxford); 2011 Oct; 50(10):1732-6. PubMed ID: 21242246
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy with not yet approved drugs or for not yet approved indications].
    Wollenhaupt J
    Z Rheumatol; 2001 Dec; 60(6):450-2. PubMed ID: 11826739
    [No Abstract]   [Full Text] [Related]  

  • 3. European regulatory aspects on new medicines targeted at treatment of rheumatoid arthritis.
    Kreutz G
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I92-5. PubMed ID: 10577982
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Group for the Respect of Ethics and Excellence in Science (GREES): rheumatoid arthritis section.
    Br J Rheumatol; 1998 Feb; 37(2):211-5. PubMed ID: 9569079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 6. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
    Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
    Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar drugs, myths and reality.
    Hernández-García C
    Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
    [No Abstract]   [Full Text] [Related]  

  • 8. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?
    Boers M
    Arthritis Rheum; 2003 Jun; 48(6):1481-3. PubMed ID: 12794813
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigational agents for rheumatoid arthritis.
    Merkel PA; Letourneau EN; Polisson RP
    Rheum Dis Clin North Am; 1995 Aug; 21(3):779-96. PubMed ID: 8619099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using anakinra for adult rheumatoid arthritis.
    Kastanek L
    Nurse Pract; 2002 Apr; 27(4):62-5. PubMed ID: 11984420
    [No Abstract]   [Full Text] [Related]  

  • 11. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
    Smolen JS; Boers M; Abadie EC; Breedveld FC; Emery P; Bardin T; Goel N; Ethgen DJ; Avouac BP; Dere WH; Durez P; Matucci-Cerinic M; Flamion B; Laslop A; Lekkerkerker FJ; Miossec P; Mitlak BH; Ormarsdóttir S; Paolozzi L; Rao R; Reiter S; Tsouderos Y; Reginster JY;
    Curr Med Res Opin; 2011 Feb; 27(2):315-25. PubMed ID: 21142618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time for a European consensus on the pharmacological management of early RA?
    Emery P
    J Rheumatol Suppl; 2002 Nov; 66():1-2. PubMed ID: 12435161
    [No Abstract]   [Full Text] [Related]  

  • 13. Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Nurmohamed MT; Dijkmans BA
    Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
    Kremer J
    Arthritis Rheum; 2005 Oct; 53(5):636-8. PubMed ID: 16208649
    [No Abstract]   [Full Text] [Related]  

  • 16. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis: a game changer.
    Cohen S; Emery P
    Arthritis Rheum; 2010 Sep; 62(9):2592-4. PubMed ID: 20872597
    [No Abstract]   [Full Text] [Related]  

  • 19. Key randomized trials of single agents in early rheumatoid arthritis.
    van de Putte LB
    J Rheumatol Suppl; 2002 Nov; 66():13-9. PubMed ID: 12435164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of rheumatoid arthritis.
    Jain R; Lipsky PE
    Med Clin North Am; 1997 Jan; 81(1):57-84. PubMed ID: 9012755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.